United BioSource

Sucampo Pharmaceuticals, now a part of Mallinckrodt, is dedicated to the commercialization of innovative therapeutic solutions, including AMITIZA (lubiprostone) for pediatric functional constipation and Rescula (unoprostone isopropyl) in Japan. With a commitment to advancing development therapies, the company focuses on addressing rare diseases such as Niemann-Pick Type C and Familial Adenomatous Polyposis through its pipeline products. Having over 150 years of experience, Sucampo emphasizes quality, integrity, and community outreach as part of its corporate culture. The merger with Mallinckrodt enhances its capabilities in delivering critical medical advancements to patients in need. Generated from the website

Bringing the Voice of the Patient into Drug Development

United Therapeutics Corporation is a biotechnology firm focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases. The company develops technology platforms for prostacyclin analogs, immunotherapeutic monoclonal antibodies, glycobiology and telemedicine. It performs activities for cardiovascular health, including the development of analogs of the endogenous hormone prostacyclin for the treatment of pulmonary arterial hypertension and critical limb ischemia. United Therapeutics telemedicine services are focused on patients with an array of possible cardiac arrhythmias. The company s IMA therapies are designed to combat ovarian, prostate, breast, lung, pancreatic and colorectal cancers. Its glycobiology compounds target hepatitis C and other infectious diseases. United Therapeutics strategy is balanced among mature programs, pivotal development and early-stage pipeline activities. The company is headquartered in Silver Spring, Md.